Novel Coronavirus
Showing 1 - 25 of >10,000
Coronavirus Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel
Not yet recruiting
- Coronavirus
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Recombinant novel coronavirus protein vaccine (CHO cells)
- (no location specified)
Sep 5, 2023
COVID-19 Trial in Changsha (Recombinant Novel Coronavirus vaccine (CHO Cells))
Completed
- COVID-19
- Recombinant Novel Coronavirus vaccine (CHO Cells)
-
Changsha, Hunan, ChinaHunan Provincial Center for Disease Control and Prevention
Jun 6, 2023
Coronavirus Trial in Wuhu (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant
Active, not recruiting
- Coronavirus
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Recombinant novel coronavirus protein vaccine (CHO cells)
-
Wuhu, Anhui, ChinaWannan Medical College Yijishan Hospital
May 6, 2023
COVID-19 Trial in Beijing (SA55 nasal spray)
Recruiting
- COVID-19
- SA55 nasal spray
-
Beijing, Chaoyang, ChinaBeijing Ditan Hospital Capital Medical University
Sep 15, 2023
COVID-19 Trial (Ursodeoxycholic acid)
Not yet recruiting
- COVID-19
- Ursodeoxycholic acid
- (no location specified)
Dec 20, 2022
Novel COVID-19-Infected Pneumonia Trial in Changsha (Jaktinib HCl tablets)
Not yet recruiting
- Novel COVID-19-Infected Pneumonia
- Jaktinib hydrochloride tablets
-
Changsha, Hunan, ChinaChangsha Taihe Hospital
Jan 9, 2023
Novel COVID-19-Infected Pneumonia Trial in Chengdu (Jaktinib HCl tablets)
Not yet recruiting
- Novel COVID-19-Infected Pneumonia
- Jaktinib hydrochloride tablets
-
Chengdu, Sichuan, ChinaWest China Hospital Sichuan University
Jan 9, 2023
COVID-19 Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Placebo)
Not yet recruiting
- COVID-19
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Placebo
- (no location specified)
Sep 22, 2023
Vaccination Refusal, COVID-19 Trial in Baltimore (Factual messages, Narrative message, Mixed message)
Completed
- Vaccination Refusal
- COVID-19
- Factual messages
- +2 more
-
Baltimore, MarylandJohns Hopkins Bloomberg School of Public Health
Mar 1, 2023
Exclusive Breastfeeding in Infants of Mothers Infected With
Completed
- Covid19
- +2 more
- RT-PCR for SARS-Cov-2
-
Istanbul, Kucukcekmece, TurkeyKanuni Sultan Suleyman Training and Research Hospital
Nov 18, 2022
COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus
Completed
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
-
Taizhou, Jiangsu, ChinaTaixing City center for Disease Control and Prevention
Oct 28, 2022
COVID-19 Infection Trial in Nanjing, Nantong, Xuzhou (no intervention)
Recruiting
- COVID-19 Infection
- no intervention
-
Nanjing, Jiangsu, China
- +2 more
Jan 28, 2023
Novel Coronavirus Pneumonia Trial in Xinxiang (NK Cells)
Recruiting
- Novel Coronavirus Pneumonia
- NK Cells
-
Xinxiang, Henan, ChinaThe First Affiliated Hospital of Xinxiang Medical University
Aug 31, 2022
COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel
Active, not recruiting
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
-
Yancheng, Jiangsu, ChinaFuning Center for Disease Control and Prevention
Oct 28, 2022
Corona Virus Disease 2019(COVID-19) Trial in Chengdu (0.3ml of mRNA vaccine)
Enrolling by invitation
- Corona Virus Disease 2019(COVID-19)
- 0.3ml of mRNA vaccine
-
Chengdu, ChinaWest China Second University Hospital
Oct 3, 2022
COVID-19 Trial in Tashkent (Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel
Recruiting
- COVID-19
- Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
-
Tashkent, UzbekistanUzbekistan, Tashkent city, Said baraka street 10
Nov 11, 2022
Covid19, Hydrogen-oxygen Gas, AMS-H-03 Trial in Guangzhou (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, OLO-1 Medical
Not yet recruiting
- Covid19
- +2 more
- Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03
- OLO-1 Medical Molecular Sieve Oxygen Generator
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital of Guangzhou Medical University
Mar 12, 2023
Oncology Patients to Novel Coronavirus Vaccines (IROC)
Recruiting
- Cancer
- COVID-19 Vaccination
-
Carmel, Indiana
- +1 more
Aug 2, 2022
COVID-19 Vaccine Trial in Ciudad autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aires
Active, not recruiting
- COVID-19 Vaccine
- Ad5-nCov
-
Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina
- +2 more
Sep 28, 2022
Long-term Impact of Infection With Novel Coronavirus (COVID-19)
Recruiting
- COVID
-
San Francisco, CaliforniaZuckerberg San Francisco General Hospital (ZSFG)
Mar 22, 2022
COVID-19 Pneumonia, Pneumonia Trial in Shenzhen (Jaktinib HCl tablets, Placebo)
Not yet recruiting
- COVID-19 Pneumonia
- Pneumonia
- Jaktinib hydrochloride tablets
- Placebo
-
Shenzhen, Guangdong, ChinaThe Third People Hospital of Shenzhen
Jan 26, 2023
Acute Pancreatitis Complicated With COVID-19
Not yet recruiting
- Acute Pancreatitis
- 2019 Novel Coronavirus Infection
- (no location specified)
Feb 13, 2023
Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases
Active, not recruiting
- Covid19
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 15, 2022